Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Trading Statement

23 Jan 2009 07:00

RNS Number : 1281M
Cyprotex PLC
23 January 2009
 



Press Release 

23 January 2009

Cyprotex PLC

("Cyprotex" or "the Company")

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, announces a trading update on its performance in the calendar year ending 31 December 2008.

Trading in the months of November and December 2008 was stronger than anticipated and as a result the Directors expect 2008 full year net profits (including significant adjustments for non-recurring costs) to be in excess of the current market expectations 

- Ends -

For further information:

Cyprotex PLC 

Dr. Anthony Baxter

Chief Executive Officer 

Tel: +44 (0) 1625 505 100 

ir@cyprotex.com  

www.cyprotex.com 

Nomura Code Securities Limited

Charles Walker, Corporate Finance

Tel: +44 (0) 20 7776 1200

cew@nomuracode.com 

www.codesecurities.com 

Media enquiries:

Pelham PR

Simon Miller

Tel: +44 (0) 20 3178 4419

simon.miller@pelhampr.com 

www.pelhampr.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAPFAAADNEFE
Date   Source Headline
7th Apr 20164:11 pmRNSForm 8.3 - Cyprotex PLC
7th Apr 20161:42 pmRNSForm 8.3 - Cyprotex
7th Apr 20169:37 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
6th Apr 20169:19 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
5th Apr 20163:10 pmRNSForm 8.3 - Cyprotex PLC
5th Apr 20169:30 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th Apr 201612:36 pmBUSForm 8.3 - Cyprotex Plc
4th Apr 201612:01 pmRNSForm 8.3 - Cyprotex plc
4th Apr 201610:32 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th Apr 201610:31 amPRNForm 8.3 - Cyprotex Plc
1st Apr 20163:58 pmRNSForm 8.3 - Cyprotex Plc
1st Apr 20167:02 amRNSStrategic Review
1st Apr 20167:01 amRNSNotice of General Meeting
1st Apr 20167:00 amRNSFinal Results
31st Mar 201610:58 amRNSLaunch of Advanced 3D Liver Model
29th Mar 20167:00 amRNSChanges to UK reporting framework
9th Mar 20167:00 amRNSLaunch of New Chemical and Cosmetics Testing Guide
10th Feb 20167:00 amRNSStrategic partnering deal with Cytocentrics
21st Jan 20167:00 amRNSExecutive Option Scheme
17th Dec 20159:09 amRNSTrading Update
17th Nov 20157:00 amRNSLaunch of Solution to Predict Preclinical Toxicity
23rd Oct 20157:00 amRNSTrading Update
15th Oct 20157:00 amRNSLaunch of New ADME Guide
13th Oct 20157:00 amRNSPartnership in the EC funded EU-ToxRisk consortium
8th Oct 20157:00 amRNSConversion of Loan Notes, Directors Dealing & TVR
21st Sep 20158:40 amRNSHolding(s) in Company
19th Aug 201512:02 pmRNSHolding(s) in Company
18th Aug 20157:00 amRNSInterim Results 2015
16th Jul 20157:00 amRNSLaunch of new Biosciences division
14th Jul 20157:00 amRNSLaunch of new chemPK workflow solution
10th Jul 201510:32 amRNSHolding(s) in Company - REPLACEMENT
10th Jul 201510:29 amRNSHolding(s) in Company - REPLACEMENT
9th Jul 20151:01 pmRNSHolding(s) in Company
9th Jul 20151:00 pmRNSHolding(s) in Company
17th Jun 201510:26 amRNSResult of AGM
1st Jun 20157:00 amRNSTrading Update
22nd May 20157:00 amRNSPublication of Annual Report & Notice of AGM
6th May 20157:02 amRNSHolding(s) in Company
15th Apr 20157:00 amRNSFinal Results
14th Apr 20157:00 amRNSLaunch of in vitro service using 3D microtissues
31st Mar 20157:00 amRNSLaunch of new laboratory in its US facility
19th Mar 20157:00 amRNSLaunch of Short Time Exposure Service
12th Mar 20157:00 amRNSAppointment of Leader of Drug Transporter Team
22nd Dec 201412:12 pmRNSDirector Dealing
19th Nov 20141:26 pmRNSDirector Dealing 19 November 2014
14th Nov 20143:34 pmRNSDirector Dealing 14 November 2014
14th Nov 20147:00 amRNSTrading Update
13th Nov 20145:17 pmRNSHolding(s) in Company
14th Oct 20147:00 amRNSEnhanced SenCeeTox® technology
13th Oct 20142:14 pmRNSConversion of Loan Notes & TVR (Replacement)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.